Jan 13 (Reuters) - The chief executive of health insurer
Aetna Inc on Tuesday said that the company had not yet
decided which hepatitis C drugs to cover now that there are two
breakthrough treatments on the market, but said that the company
was actively working on a decision.
Investors are watching closely to see how insurers decide to
cover these drugs, which cost tens of thousands of dollars per
treatment, after AbbVie Inc started a competitor to Gilead
Sciences' breakthrough hepatitis C treatment.
Labels: Aetna, coverage